MTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Meritage Homes Corp (MTH) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock's technical indicators suggest a bearish trend, and the company's recent financial performance shows significant declines in revenue, net income, and gross margin. While there are positive catalysts such as hedge fund buying and some optimistic analyst ratings, the overall sentiment is mixed, and the stock lacks strong momentum or clear growth drivers in the near term. For a long-term investor, it may be better to wait for more favorable conditions or stronger signals of recovery.
The stock is in a bearish trend with a negatively expanding MACD histogram (-1.084), an oversold RSI (15.385), and converging moving averages. The current pre-market price ($68.94) is near the S1 support level ($69.873), with further downside risk to S2 ($67.252).
Hedge funds are increasing their positions in the stock, with a 123.32% increase in buying over the last quarter. Some analysts, such as Truist and UBS, maintain a Buy rating, citing long-term potential and valuation appeal.
Insiders are selling heavily, with a 383.22% increase in selling activity over the last month. The company's financial performance in Q4 2025 showed significant declines across key metrics, including revenue (-11.47% YoY), net income (-51.33% YoY), and gross margin (-44.44% YoY). Additionally, the homebuilding environment remains challenging, as noted by analysts.
In Q4 2025, Meritage Homes reported a revenue decline of -11.47% YoY to $1.44 billion, net income dropped -51.33% YoY to $84.03 million, EPS fell -49.15% YoY to $1.2, and gross margin decreased -44.44% YoY to 9.34%. These figures indicate significant financial headwinds.
Analyst sentiment is mixed. Truist initiated coverage with a Buy rating and a $90 price target, citing the company's differentiated strategy. UBS maintains a Buy rating but has lowered its price target to $95 from $101. BofA downgraded the stock to Neutral, citing downside risks to gross margins and valuation concerns. Keefe Bruyette also lowered its price target to $76, maintaining a Market Perform rating.
